Evidence map›Paper›PMID 30816419›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.

Louise Geddes, Jenny Iversen, Handan Wand, Aryan Esmaeili, Judith Tsui, Margaret Hellard, Gregory Dore, Jason Grebely, Paul Dietze, Julie Bruneau and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 4 countries.

Louise GeddesKirby Institute, University of New South Wales Sydney, Australia.
Jenny IversenKirby Institute, University of New South Wales Sydney, Australia.
Handan WandKirby Institute, University of New South Wales Sydney, Australia.
Aryan EsmaeiliClinical Research Education, Icahn School of Medicine at Mount Sinai, New York.
Judith TsuiUniversity of Washington School of Medicine, Seattle.
Margaret HellardBurnet Institute, Melbourne, Victoria, Australia.
Gregory DoreKirby Institute, University of New South Wales Sydney, Australia.
Jason GrebelyKirby Institute, University of New South Wales Sydney, Australia.
Paul DietzeBurnet Institute, Melbourne, Victoria, Australia.
Julie BruneauLe Centre de recherche du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Quebec, Canada.
Maria PrinsCluster Infectious Diseases, Public Health Service of Amsterdam, The Netherlands.
Megan D MorrisUniversity of California, San Francisco.
Naglaa H ShoukryLe Centre de recherche du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Quebec, Canada.
Andrew R LloydKirby Institute, University of New South Wales Sydney, Australia.
Arthur Y KimHarvard Medical School, Boston, Massachusetts.
Georg LauerHarvard Medical School, Boston, Massachusetts.
Andrea L CoxDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland.
Kimberly PageUniversity of New Mexico Health Sciences Center, Albuquerque.
Lisa MaherKirby Institute, University of New South Wales Sydney, Australia.
International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative
UNSW Sydney · AUBurnet Institute · AUCentre Hospitalier de l’Université de Montréal · CAHarvard University · USGGD Amsterdam · NLIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USUniversity of California, San Francisco · USUniversity of New Mexico · USUniversity of Washington · US

Funding

Tracking and EvaluationU54GM104944 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI MARCHAND, GWEN · 2013 to 2023
$39.6M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
CIHR MOP-103138CIHR MOP-19106468NCATS NIH HHS UL1 TR001449NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI088791NIDA NIH HHS R01 DA015999NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA031056NIGMS NIH HHS U54 GM104944
6 · The paper itself

Abstract

backgroundWhile opioid agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inject drugs (PWID), protective effects may be attenuated in females. We used pooled data from an international collaboration of prospective cohorts to assess sex disparities in HCV incidence among PWID exposed to OAT.

methodsIndependent predictors of HCV infection were identified using Cox regression models with random effects after accounting for the clustering effect of study sites. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are presented in sex-specific analyses.

resultsAmong 701 participants exposed to OAT, HCV incidence was 16.5/100 person-years of observation (PYO) (95% CI, 13.1-20.7) in females and 7.6/100 PYO (95% CI, 6.0-9.5) in males (female:male adjusted HR [aHR], 1.80 [95% CI, 1.37-2.22]; P < .001). Factors associated with HCV acquisition among females exposed to OAT included nonwhite race (aHR, 1.79 [95% CI, 1.25-2.56]; P = .001), unstable housing (aHR, 4.00 [95% CI, 3.62-4.41]; P < .001), daily or more frequent injection (aHR, 1.45 [95% CI, 1.01-2.08]; P = .042), and receptive syringe sharing (aHR, 1.43 [95% CI, 1.33-1.53]; P < .001).

conclusionsFemale PWID exposed to OAT are twice as likely as their male counterparts to acquire HCV. While there is a need for better understanding of sex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, structural and behavioral interventions that target women are required to bolster the efficacy of OAT in preventing HCV transmission.

Indexed as

Hepatitis CSubstance Abuse, IntravenousAnalgesics, OpioidFemaleHepacivirusHumansMaleProspective StudiesAnalgesics, Opioidharm reductionopioid agonist therapypeople who inject drugssex; hepatitis C virus

Identifiers

PMID30816419
PMCPMC6912156
OpenAlexW2919155466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.